Xanitrol™ is
clinically proven

1. Xanitrol™ significantly reduces the body weight and body fat of overweight and obese subjects, leading to a healthier body composition.

A double-blind, randomised, placebo-controlled, bicentric clinical investigation evaluated the safety and efficacy of Xanitrol™ in reducing the body weight of 91 overweight and obese subjects.
Click here to read the full study published in PHYTOTHERAPY RESEARCH, 2014.

Primary endpoints:
After 12 weeks, subjects on Xanitrol™ experienced a significantly greater reduction in mean body weight and body fat mass.

The change in mean body weight between the two groups was significantly different at week 12; subjects in the Xanitrolâ„¢ group lost a mean of 2.26 kg while subjects in the placebo group gained a mean of 0.56 kg.

The change in mean body fat mass between the two groups was significantly different at week 12; subjects in the Xanitrol™ group lost a mean of 1.12 kg, while subjects in the placebo group gained 0.37 kg.

 

Previous | Next

 
Copyright © 2015 by InQpharm Group. All rights reserved. Last updated: Nov 2015 | ID: FX/TM/EN/15/001
Xanitrol and InQpharm are trademarks of the InQpharm group of companies.